167 related articles for article (PubMed ID: 37275863)
1. Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response.
Li Z; Li Y; Tian Y; Li N; Shen L; Zhao Y
Front Immunol; 2023; 14():1170539. PubMed ID: 37275863
[TBL] [Abstract][Full Text] [Related]
2. Pancancer landscape analysis of the thymosin family identified TMSB10 as a potential prognostic biomarker and immunotherapy target in glioma.
Xiong Y; Qi Y; Pan Z; Wang S; Li B; Feng B; Xue H; Zhao R; Li G
Cancer Cell Int; 2022 Sep; 22(1):294. PubMed ID: 36163046
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Relevance and Functional Implications of Thymosin Beta-10 in Glioma.
Li W; Chen J; Xiang C; Long Y; Wu K; Li J
Genet Res (Camb); 2023; 2023():5517445. PubMed ID: 38026448
[TBL] [Abstract][Full Text] [Related]
4. Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer.
Zhang X; Ren D; Guo L; Wang L; Wu S; Lin C; Ye L; Zhu J; Li J; Song L; Lin H; He Z
Breast Cancer Res; 2017 Feb; 19(1):15. PubMed ID: 28179017
[TBL] [Abstract][Full Text] [Related]
5. Thymosin β 10 is overexpressed and associated with unfavorable prognosis in hepatocellular carcinoma.
Song C; Su Z; Guo J
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30787051
[TBL] [Abstract][Full Text] [Related]
6. TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
Pan Q; Cheng G; Liu Y; Xu T; Zhang H; Li B
Int J Oncol; 2020 May; 56(5):1101-1114. PubMed ID: 32319572
[TBL] [Abstract][Full Text] [Related]
7. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
Front Immunol; 2022; 13():844736. PubMed ID: 35592314
[TBL] [Abstract][Full Text] [Related]
8. Thymosin β10 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma.
Zeng J; Yang X; Yang L; Li W; Zheng Y
Respir Res; 2020 Dec; 21(1):328. PubMed ID: 33349268
[TBL] [Abstract][Full Text] [Related]
9. TMSB10, a potential prognosis prediction biomarker, promotes the invasion and angiogenesis of gastric cancer.
Yan Z; Yan Q; Song Y; Wang L
J Gastroenterol Hepatol; 2021 Nov; 36(11):3102-3112. PubMed ID: 34114679
[TBL] [Abstract][Full Text] [Related]
10. TMSB10 Promotes Progression of Clear Cell Renal Cell Carcinoma via JUN Transcription Regulation.
Wang C; He Y; You Z; Chen X
Ann Clin Lab Sci; 2022 Mar; 52(2):230-239. PubMed ID: 35414502
[TBL] [Abstract][Full Text] [Related]
11. Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity.
Wu Y; Lin Z; Tang X; Tong Z; Ji Y; Xu Y; Zhou Z; Yang J; Li Z; Liu T
Front Immunol; 2023; 14():1182030. PubMed ID: 37388742
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract][Full Text] [Related]
13. DNMT1 maintains the methylation of miR-152-3p to regulate TMSB10 expression, thereby affecting the biological characteristics of colorectal cancer cells.
Wang C; Ma X; Zhang J; Jia X; Huang M
IUBMB Life; 2020 Nov; 72(11):2432-2443. PubMed ID: 32918845
[TBL] [Abstract][Full Text] [Related]
14. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
[TBL] [Abstract][Full Text] [Related]
15. PTEN/AKT upregulation of TMSB10 contributes to lung cancer cell growth and predicts poor survival of the patients.
Li J; Zhou S; Li H; Xu Y; Zhou N; Liu R
Biosci Biotechnol Biochem; 2021 Mar; 85(4):805-813. PubMed ID: 33686397
[TBL] [Abstract][Full Text] [Related]
16. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.
Tu Z; Ouyang Q; Long X; Wu L; Li J; Zhu X; Huang K
Front Immunol; 2022; 13():837512. PubMed ID: 35401558
[TBL] [Abstract][Full Text] [Related]
17. Predictive role of E2F6 in cancer prognosis and responses of immunotherapy.
Gong C; Tu Z; Long X; Liu X; Liu F; Liu J; Zhu X; Li J; Huang K
Int Immunopharmacol; 2024 Jan; 127():111302. PubMed ID: 38071912
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
19. TMSB10 promotes migration and invasion of cancer cells and is a novel prognostic marker for renal cell carcinoma.
Xiao R; Shen S; Yu Y; Pan Q; Kuang R; Huang H
Int J Clin Exp Pathol; 2019; 12(1):305-312. PubMed ID: 31933746
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of thymosin β10 correlates with disease progression and poor prognosis in bladder cancer.
Wang B; Wang Z; Zhang T; Yang G
Exp Ther Med; 2019 Nov; 18(5):3759-3766. PubMed ID: 31616507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
